6-Aminohexanoic acid

131.17

131.17

906872

200-469-3

U6F3787206

755867|400230|212532|26154

DTXSID0020070

C47391

FINE, WHITE, CRYSTALLINE POWDER|LEAVES FROM ETHER

B - Blood and blood forming organs

29224995

63.3

-2.95

white powder

1.03 g/mL at 20 °C

202-203 °C

255.6°C at 760 mmHg

207-209°C

H2O: 50 mg/mL

2-8°C

<0.1 hPa (20 °C)

Peritoneal-rat LD50: 7000 mg/kg; oral-mouse LD50: 14300 mg/kg

Flammable; burning produces toxic nitrogen oxide fumes

ODORLESS, OR NEARLY SO

TASTELESS

4.43(at 25 °C)

4.43 (at 25 °C)|PK1= 4.43; PK2= 10.75

130.2 Ų [M+H]+

2

36/37/38

26-36

MO6300000

Xi

Warehouse ventilated, low temperature and dry

STABLE IN LIGHT & AIR

P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, P501

H315

REVIEW: A PROFILE OF THE PHARMACOLOGY, THERAPEUTIC INDICATIONS, THE PREPARATIONS AND STRENGTHS AVAILABLE, THE DOSAGE, CONTRAINDICATIONS, TOXICITY, INTERACTIONS, PHARMACOKINETICS AND OTHER PHYSICAL PROPERTIES OF EPSILON-AMINOCAPROIC ACID.[PROFILE ON EPSILON AMINOCAPROIC ACID; AUST J PHARM 62(JUN) 403 (1981)]

|Warning|H315 (96.36%): Causes skin irritation [Warning Skin corrosion/irritation]|P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 153 companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

practically nontoxic

A few cases of acute overdosage with intravenous administration have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. The intravenous and oral LD50 were 3.0 and 12.0 g/kg respectively in the mouse and 3.2 and 16.4 g/kg respectively in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog.

PLASMINOGEN ACTIVATORS SUCH AS STREPTOKINASE & UROKINASE ARE USED TO TREAT THROMBOEMBOLIC DISORDERS. ...AMINOCAPROIC ACID COUNTERACTS THE THROMBOLYTIC EFFECT OF THESE DRUGS...

For use in the treatment of excessive postoperative bleeding.|FDA Label

Antifibrinolytic Agents|...USED IN TREATMENT OF PROCEDURES OR DISORDERS IN WHICH FIBRINOLYSIS IS ENHANCED...CARDIAC BYPASS, POSTCAVAL SHUNT, MAJOR THORACIC SURGERY, PROSTATIC POSTOPERATIVE HEMATURIA...NONSURGICAL HEMATURIA, LEUKEMIA, METASTATIC PROSTATIC CARCINOMA, CIRRHOSIS & OTHER HEPATIC DISEASES, ECLAMPSIA, INTRAUTERINE FETAL DEATH, AMNIOTIC FLUID EMBOLISM & ABRUPTIO PLACENTAE. THE DRUG IS OF NO VALUE IN HEMORRHAGE DUE TO THROMBOCYTOPENIA, HYPERHEPARINEMIA, OR OTHER COAGULATION DEFECTS, OR TO VASCULAR DISRUPTION.|FOR IV ADMIN...SHOULD BE DILUTED IN ISOTONIC OR DEXTROSE SOLN & INJECTED SLOWLY. AFTER 8 HR TREATMENT, PATIENT'S CONDITION SHOULD BE REEVALUATED.|...SPECIFIC ANTIDOTE FOR AN OVERDOSE OF A FIBRINOLYTIC AGENT. ...|For more Therapeutic Uses (Complete) data for 6-AMINOCAPROIC ACID (9 total), please visit the HSDB record page.

RAPID IV ADMIN SHOULD BE AVOIDED TO PREVENT HYPOTENSION, BRADYCARDIA, & OTHER ARRHYTHMIAS.|...TERATOGENIC IN ANIMALS & HENCE SHOULD NOT BE USED IN HUMANS IN FIRST 2 TRIMESTERS OF PREGNANCY & IN THIRD TRIMESTER ONLY IF ITS USE IS IMPERATIVE.|IF AMINOCAPROIC ACID IS GIVEN TO PT WITH DIC /DIFFUSE INTRAVASCULAR COAGULATION/ IT MAY CAUSE SERIOUS OR EVEN FATAL THROMBUS FORMATION. ...MOST EXPERTS DO NOT USE AMINOCAPROIC ACID TO TREAT "FIBRINOLYTIC" HEMORRHAGE UNLESS THERE IS DEFINITIVE PROOF THAT DIC IS NOT THE UNDERLYING CAUSE.|WHEN AMINOCAPROIC ACID IS GIVEN DURING SURGERY, CARE MUST BE TAKEN TO FREE THE BODY CAVITIES OF BLOOD CLOTS SINCE THE DRUG REMAINS IN HIGH CONCN IN THE CLOTS, THEREBY INHIBITING THEIR PHYSIOLOGIC DISSOLUTION.|INCIDENCE OF THROMBOTIC EVENTS SECONDARY TO INHIBITION OF FIBRINOLYTIC SYSTEM BY DRUG IS UNKNOWN, BUT MAY BE PARTICULARLY INCR IN PT WITH UNDERLYING PREDISPOSITION TO DEVELOP THROMBOSIS.

Aminocaproic acid works as an antifibrinolytic. It is a derivative of the amino acid lysine. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Aminocaproic acid may be a possible prophylactic for vascular disease, as it may prevent formation of lipoprotein (a), a risk factor for vascular disease.

Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders. (See all compounds classified as Antifibrinolytic Agents.)

Absorbed rapidly following oral administration. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1).|Renal excretion is the primary route of elimination, whether aminocaproic acid is administered orally or intravenously.|23.1 ± 6.6 L|169 mL/min|AMINOCAPROIC ACID IS WELL ABSORBED ORALLY... THIS DRUG IS EXCRETED RAPIDLY IN URINE, LARGELY UNCHANGED, & PEAK PLASMA LEVELS ARE OBTAINED ABOUT 2 HR AFTER A SINGLE ORAL DOSE.

Sixty-five percent of the dose is recovered in the urine as unchanged drug and 11% of the dose appears as the metabolite adipic acid.

The terminal elimination half-life is approximately 2 hours.

Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks the binding of plasminogen to fibrin and its activation to plasmin. With NO activation of plasmin, there is a reduction in fibrinolysis. This consequently will reduce the amount of bleeding post surgery. Elevated plasma levels of lipoprotein(a) have been shown to increase the risk of vascular disease. Lipoprotein 9a)a has two components, apolipoprotein B-100, linked to apolipoprotein (a). Aminocaproic acid may change the conformation of apoliprotein (a), changing its binding properties and potentially preventing the formation of lipoprotein (a).|A COMPETITIVE INHIBITOR OF ACTIVATORS OF PROFIBRINOLYSIN &, TO LESSER EXTENT, OF FIBRINOLYSIN. AS A CONSEQUENCE, IT SUPPRESSES FORMATION OF FIBRINOLYSIN, AN ENZYME WHICH DESTROYS FIBRINOGEN, FIBRIN, & OTHER CLOTTING COMPONENTS.|MICROCALORIMETRY AND UV AND IR SPECTROSCOPY WERE USED TO STUDY THE INTERMOLECULAR INTERACTIONS OF PLASMINOGEN AND PLASMIN WITH EPSILON-AMINOCAPROIC ACID (I) TO DETERMINE THE MECHANISM OF FIBRINOLYSIS INHIBITION. AT LOW DOSES, THE INHIBITORY EFFECT WAS DUE MAINLY TO BLOCKADE OF THE STAGE OF ACTIVATION OF PLASMINOGEN, WHEREAS THE EFFECTIVENESS OF HIGH CONCENTRATIONS OF I WAS ACHIEVED ALSO BY INACTIVATION OF THE ENZYMIC ACTIVITY OF PLASMIN.

CARDIAC & HEPATIC NECROSES WERE FOUND @ POSTMORTEM EXAMINATION IN ONE PT WHO HAD RECEIVED THERAPEUTIC DOSES OF THE DRUG.|AMINOCAPROIC ACID MAY CAUSE ITCHING, ERYTHEMA, SKIN RASH, DIURESIS, HEARTBURN, NAUSEA, & DIARRHEA. ...HAS ANTIADRENERGIC EFFECT SIMILAR TO GUANETHIDINE, SO THAT NASAL STUFFINESS, CONJUNCTIVAL SUFFUSION, & HYPOTENSION MAY OCCUR. ...MAY ENHANCE THROMBOTIC PROCESSES BY SUPPRESSION OF REACTIVE FIBRINOLYSIS...|AMICAR HAS BEEN USED IN SUBARACHNOID HEMORRHAGE TO PROMOTE CLOTTING, BUT CEREBRAL THROMBOSIS HAS BEEN REPORTED IN VARIOUS VASCULAR COMPARTMENTS FOLLOWING ITS USE. TWO PATIENTS ARE DESCRIBED WHO HAD CEREBRAL ANGIOGRAPHY AFTER AMICAR THERAPY WHICH DEMONSTRATED THROMBOSIS UNRELATED TO VASCULAR SPASM OR TO TECHNICAL COMPLICATIONS OF ANGIOGRAPHY.

6 Aminocaproic Acid

EXCLUDING CAPTIVE USE IN NYLON 6 PRODUCTION FROM CAPROLACTAM, PROBABLY 100% IS USED AS A FIBRINOLYTIC INHIBITOR (1976)

...AVAILABLE AS INJECTION (250 MG/ML), SYRUP (250 MG/ML) & TABLETS (500 MG).

Hexanoic acid, 6-amino-: ACTIVE

A GAS CHROMATOGRAPHIC METHOD FOR SEPARATING 6-AMINOCAPROIC ACID FROM AMINO ACIDS NORMALLY PRESENT IN BIOLOGICAL FLUIDS DESCRIBED.

6-AMINOCAPRIOC ACID WAS DETERMINED IN HUMAN SERUM BY HIGH PERFORMANCE LIQ CHROMATOGRAPHY. METHOD HAD A PRECISION OF 4.4%.

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients|Fatty Acyls [FA] -> Fatty Acids and Conjugates [FA01] -> Amino fatty acids [FA0110]|Pharmaceuticals -> Animal Drugs -> Approved in Taiwan